Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function.
暂无分享,去创建一个
R. Neve | U. Nielsen | C. Benz | J. Marks | D. Kirpotin | M. Poul | James D. Marks | C. C. Benz | Richard M. Neve | Ulrik Nielsen
[1] U. Nielsen,et al. Selection of tumor-specific internalizing human antibodies from phage libraries. , 2000, Journal of molecular biology.
[2] Monilola A. Olayioye,et al. The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.
[3] C. Benz,et al. Emerging antibody-based HER2 (ErbB-2/neu) therapeutics. , 2000, Breast disease.
[4] John M. Daly,et al. ErbB2 Potentiates Breast Tumor Proliferation through Modulation of p27Kip1-Cdk2 Complex Formation: Receptor Overexpression Does Not Determine Growth Dependency , 2000, Molecular and Cellular Biology.
[5] R. Neve,et al. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells , 2000, Oncogene.
[6] W. Muller,et al. Signal transduction in mammary tumorigenesis: a transgenic perspective , 2000, Oncogene.
[7] G. Mills,et al. Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[8] N. Robert,et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J. Marks,et al. Toward selection of internalizing antibodies from phage libraries. , 1999, Biochemical and biophysical research communications.
[10] H. Gibbs,et al. Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact? , 1999, Seminars in oncology.
[11] J. Mendelsohn,et al. Heregulin Regulates Cytoskeletal Reorganization and Cell Migration through the p21-activated Kinase-1 via Phosphatidylinositol-3 Kinase* , 1998, The Journal of Biological Chemistry.
[12] G. Adams,et al. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. , 1998, British Journal of Cancer.
[13] Yosef Yarden,et al. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors , 1997, Oncogene.
[14] N. Hynes,et al. ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.
[15] Kuo-Fen Lee,et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development , 1995, Nature.
[16] J. Huston,et al. In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. , 1995, Immunotechnology : an international journal of immunological engineering.
[17] Y. Yarden,et al. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[18] N. Hynes,et al. The biology of erbB-2/neu/HER-2 and its role in cancer. , 1994, Biochimica et biophysica acta.
[19] N. Hynes,et al. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. , 1993, British Journal of Cancer.
[20] C. Hopkins,et al. Signal-dependent membrane protein trafficking in the endocytic pathway. , 1993, Annual review of cell biology.
[21] Yosef Yarden,et al. Isolation of the Neu HER-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cells , 1992, Cell.
[22] A. Ullrich,et al. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[23] A. Ullrich,et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor , 1989, Molecular and cellular biology.